[1]
|
Smyth, E.C., Nilsson, M., Grabsch, H.I., van Grieken, N.C. and Lordick, F. (2020) Gastric Cancer. The Lancet, 396, 635-648. https://doi.org/10.1016/S0140-6736(20)31288-5
|
[2]
|
季加孚. 胃癌外科的现状与发展趋势[J]. 中国普外基础与临床杂志, 2006(1): 1-3.
|
[3]
|
邹文斌, 李兆申. 中国胃癌发病率及死亡率研究进展[J]. 中国实用内科杂志, 2014, 34(4): 408-415.
|
[4]
|
Ferrara, N. (2004) Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endocrine Reviews, 25, 581-611. https://doi.org/10.1210/er.2003-0027
|
[5]
|
Carmeliet, P. (2005) VEGF as a Key Mediator of Angiogenesis in Cancer. Oncology, 69, 4-10.
https://doi.org/10.1159/000088478
|
[6]
|
Xu, D., Wang, T.L., Sun, L.P. and You, Q.D. (2019) Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents. Mini-Reviews in Medicinal Chemistry, 11, 18-31. https://doi.org/10.2174/138955711793564015
|
[7]
|
Simons, M., Gordon, E. and Claesson-Welsh, L. (2016) Mechanisms and Regulation of Endothelial VEGF Receptor Signalling. Nature Reviews Molecular Cell Biology, 17, 611-625. https://doi.org/10.1038/nrm.2016.87
|
[8]
|
Pepper, M.S., Ferrara, N., Orci, L. and Montesano, R. (1992) Potent Synergism between Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in the Induction of Angiogenesis in Vitro. Biochemical and Biophysical Research Communications, 189, 824-831. https://doi.org/10.1016/0006-291X(92)92277-5
|
[9]
|
Song, G., Li, Y. and Jiang, G. (2019) Role of VEGF/VEGFR in the Pathogenesis of Leukemias and as Treatment Targets (Review). Oncology Reports, 28, 1935-1944. https://doi.org/10.3892/or.2012.2045
|
[10]
|
Cai, S.X. (2018) Small Molecule Vascular Disrupting Agents: Potential New Drugs for Cancer Treatment. Recent Patents on Anti-Cancer Drug Discovery, 2, 79-101. https://doi.org/10.2174/157489207779561462
|
[11]
|
Yamashita-Kashima, Y., Fujimoto-Ouchi, K., Yorozu, K., Ku-rasawa, M., Yanagisawa, M., Yasuno, H. and Mori, K. (2021) Biomarkers for Antitumor Activity of Bevacizumab in Gastric Cancer Models. BMC Cancer, 12, Article No. 37.
https://doi.org/10.1186/1471-2407-12-37
|
[12]
|
Ohtsu, A., Shah, M.A., Van Cutsem, E., Rha, S.Y., Sawaki, A., Park, S.R., et al. (2020) Bevacizumab in Combination with Chemotherapy as First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. Clinical Oncology, 29, 3968-3976. https://doi.org/10.1200/JCO.2011.36.2236
|
[13]
|
Van Cutsem, E., de Haas, S., Kang, Y.K., Ohtsu, A., Tebbutt, N.C., Ming, X.J., et al. (2021) Bevacizumab in Combination with Chemotherapy as First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation from the AVAGAST Randomized Phase III Trial. Clinical Oncology, 30, 2119-2127. https://doi.org/10.1200/JCO.2011.39.9824
|
[14]
|
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.C., Bodoky, G., Shi-mada, Y., et al. (2014) Ramucirumab plus Paclitaxel versus Placebo plus Paclitaxel in Patients with Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINBOW): A Double-Blind, Randomised Phase 3 Trial. The Lancet Oncology, 15, 1224-1235.
https://doi.org/10.1016/S1470-2045(14)70420-6
|
[15]
|
Xu, R.H., Zhang, Y., Pan, H., Feng, J., Zhang, T., Liu, T., et al. (2021) Efficacy and Safety of Weekly Paclitaxel with or without Ramucirumab as Second-Line Therapy for the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (RAINBOW-Asia): A Randomised, Multicentre, Double-Blind, Phase 3 Trial. The Lancet Gastroenterology and Hepatology, 6, 1015-1024. https://doi.org/10.1016/S2468-1253(21)00313-7
|
[16]
|
Katoh, M. and Nakagama, H. (2014) FGF Receptors: Cancer Biology and Therapeutics. Medicinal Research Reviews, 34, 280-300. https://doi.org/10.1002/med.21288
|
[17]
|
Vad-Nielsen, J., Gammelgaard, K.R., Daugaard, T.F. and Nielsen, A.L. (2019) Cause-and-Effect Relationship between FGFR1 Expression and Epithelial-Mesenchymal Transition in EGFR-Mutated Non-Small Cell Lung Cancer Cells. Lung Cancer, 132, 132-140. https://doi.org/10.1016/j.lungcan.2019.04.023
|
[18]
|
Minashi, K., Yamada, T., Hosaka, H., Amagai, K., Shimizu, Y., Kiyozaki, H., Sato, M., Soeda, A., Endo, S., et al. (2021) Cancer-Related FGFR2 Overexpression and Gene Amplifica-tion in Japanese Patients with Gastric Cancer. Japanese Journal of Clinical Oncology, 51, 1523-1533. https://doi.org/10.1093/jjco/hyab104
|
[19]
|
Touat, M., Ileana, E., Postel-Vinay, S. andré, F. and Soria, J.C. (2015) Targeting FGFR Signaling in Cancer. Clinical Cancer Research, 21, 2684-2694. https://doi.org/10.1158/1078-0432.CCR-14-2329
|
[20]
|
Deng, N., Goh, L.K., Wang, H., Das, K., Tao, J., Tan, I.B., et al. (2019) A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Systematic Patterns of Molec-ular Exclusivity and Co-Occurrence among Distinct Therapeutic Targets. Gut, 61, 673-684. https://doi.org/10.1136/gutjnl-2011-301839
|
[21]
|
Xie, L., Su, X., Zhang, L., Yin, X., Tang, L., Zhang, X., et al. (2021) FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547. Clinical Cancer Research, 19, 2572-2583.
https://doi.org/10.1158/1078-0432.CCR-12-3898
|
[22]
|
Van Cutsem, E., Bang, Y.J., Mansoor, W., Petty, R.D., Chao, Y., Cunningham, D., et al. (2017) A Randomized, Open-Label Study of the Efficacy and Safety of AZD4547 Monotherapy versus Paclitaxel for the Treatment of Advanced Gastric Adenocarcinoma with FGFR2 Polysomy or Gene Amplification. Annals of Oncology, 28, 1316-1324.
https://doi.org/10.1093/annonc/mdx107
|
[23]
|
Chang, J., Wang, S., Zhang, Z., Liu, X., Wu, Z., Geng, R., et al. (2015) Multiple Receptor Tyrosine Kinase Activation Attenuates Therapeutic Efficacy of the Fibroblast Growth Factor Receptor 2 Inhibitor AZD4547 in FGFR2 Amplified Gastric Cancer. Oncotarget, 6, 2009-2022. https://doi.org/10.18632/oncotarget.2987
|
[24]
|
Wainberg, Z.A., Enzinger, P.C., Kang, Y.K., Qin, S., Yamaguchi, K., Kim, I.H., et al. (2022) Bemarituzumab in Patients with FGFR2b-Selected Gastric or Gastro-Oesophageal Junction Ad-enocarcinoma (FIGHT): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study. The Lancet Oncology, 23, 1430-1440.
https://doi.org/10.1016/S1470-2045(22)00603-9
|
[25]
|
Beenken, S.W., Grizzle, W.E., Crowe, D.R., Conner, M.G., Weiss, H.L., Sellers, M.T., et al. (2020) Molecular Biomarkers for Breast Cancer Prognosis: Coexpression of c-erbB-2 and p53. Annals of Surgery, 233, 630-638.
https://doi.org/10.1097/00000658-200105000-00006
|
[26]
|
Ullric, A., Coussens, L., Hayflick, J.S., Dull, T.J., Gray, A., Tam, A.W., et al. (1984) Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells. Nature, 309, 418-425. https://doi.org/10.1038/309418a0
|
[27]
|
Roskoski, R. (2021) The ErbB/HER Family of Protein-Tyrosine Kinases and Cancer. Pharmacological Research, 79, 34-74. https://doi.org/10.1016/j.phrs.2013.11.002
|
[28]
|
Kovacs, E., Zorn, J.A., Huang, Y., Barros, T. and Kuriyan, J. (2015) A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor. Annual Review of Biochemistry, 84, 739-764.
https://doi.org/10.1146/annurev-biochem-060614-034402
|
[29]
|
Hisamatsu, Y., Oki, E., Otsu, H. ando, K., Saeki, H., Tokunaga, E., et al. (2019) Effect of EGFR and p-AKT Overexpression on Chromosomal Instability in Gastric Cancer. Annals of Surgical Oncology, 23, 1986-1992.
https://doi.org/10.1245/s10434-016-5097-3
|
[30]
|
Lordick, F., Kang, Y.K., Chung, H.C., Salman, P., Oh, S.C., Bo-doky, G., et al. (2021) Capecitabine and Cisplatin with or without Cetuximab for Patients with Previously Untreated Ad-vanced Gastric Cancer (EXPAND): A Randomised, Open-Label Phase 3 Trial. The Lancet Oncology, 14, 490-499. https://doi.org/10.1016/S1470-2045(13)70102-5
|
[31]
|
余锋, 熊建萍, 冯苗, 项晓军, 邱峰, 张凌, 詹正宇. 西妥昔单抗增强放疗对人胃癌细胞株MGC803及BGC823的作用及其机制[J]. 肿瘤防治研究, 2010, 37(9): 996-999+1003.
|
[32]
|
Waddell, T., Chau, I., Cunningham, D., Gonzalez, D., Okines, A.F., Okines, C., et al. (2013) Epi-rubicin, Oxaliplatin, and Capecitabine with or without Panitumumab for Patients with Previously Untreated Advanced Oesophago Gastric Cancer (REAL3): A Randomised, Open-Label Phase 3 Trial. The Lancet Oncology, 14, 481-489.
https://doi.org/10.1016/S1470-2045(13)70096-2
|
[33]
|
Smyth, E.C., Vlachogiannis, G., Hedayat, S., Harbery, A., Hulkki-Wilson, S., Salati, M., et al. (2021) EGFR Amplification and Outcome in a Randomised Phase III Trial of Chem-otherapy Alone or Chemotherapy plus Panitumumab for Advanced Gastro-Oesophageal Cancers. Gut, 70, 1632-1641. https://doi.org/10.1136/gutjnl-2020-322658
|
[34]
|
Saini, K.S., Azim, H.A., Metzger-Filho, O., Loi, S., Sotiriou, C., de Azambuja, E. and Piccart, M. (2011) Beyond Trastuzumab: New Treatment Options for HER2-Positive Breast Cancer. Breast, 20, S20-S27.
https://doi.org/10.1016/S0960-9776(11)70289-2
|
[35]
|
Gerson, J.N., Skariah, S., Denlinger, C.S. and Astsaturov, I. (2017) Perspectives of HER2-Targeting in Gastric and Esophageal Cancer. Expert Opinion on Investigational Drugs, 26, 531-540.
https://doi.org/10.1080/13543784.2017.1315406
|
[36]
|
Moasser, M.M. (2019) The Oncogene HER2: Its Signaling and Transforming Functions and Its Role in Human Cancer Pathogenesis. Oncogene, 26, 6469-6487. https://doi.org/10.1038/sj.onc.1210477
|
[37]
|
Meric-Bernstam, F., Johnson, A.M., Dumbrava, E.E.I., Raghav, K., Balaji, K., Bhatt, M., et al. (2019) Advances in HER2-Targeted Therapy: Novel Agents and Opportunities beyond Breast and Gastric Cancer. Clinical Cancer Research, 25, 2033-2041. https://doi.org/10.1158/1078-0432.CCR-18-2275
|
[38]
|
Gravalos, C. and Jimeno, A. (2008) HER2 in Gastric Can-cer: A New Prognostic Factor and a Novel Therapeutic Target. Annals of Oncology, 19, 1523-1529. https://doi.org/10.1093/annonc/mdn169
|
[39]
|
Bang, Y.J., Van Cutsem, E., et al. (2010) Trastuzumab in Combina-tion with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gas-tro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. Lancet, 376, 687-797.
https://doi.org/10.1016/S0140-6736(10)61121-X
|
[40]
|
Bang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
|
[41]
|
Al-Shamsi, H.O., Fahmawi, Y., Dahbour, I., Tabash, A., Rogers, J.E., Mares, J.E., et al. (2021) Continuation of Trastuzumab beyond Disease Progression in HER2-Positive Metastatic Gastric Cancer: The MD Anderson Experience. Journal of Gastrointestinal Oncology, 7, 499-505. https://doi.org/10.21037/jgo.2016.06.16
|
[42]
|
Gianni, L., Pienkowski, T., Im, Y.H., Roman, L., Tseng, L.M., Liu, M.C., et al. (2012) Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women with Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (NeoSphere): A Randomised Multicentre, Open-Label, Phase 2 Trial. The Lancet Oncology, 13, 25-32.
https://doi.org/10.1016/S1470-2045(11)70336-9
|
[43]
|
Scartozzi, M., Giampieri, R., Del Prete, M., Faloppi, L., Bianconi, M., Vincenzi, B., Tonini, G., Santini, D. and Cascinu, S. (2014) Selected Gastrointestinal Cancer Presentations from the American Society of Clinical Oncology Annual Meeting 2013 in Review: It Is Not about the Destination, It Is about the Journey. Expert Opinion on Pharmacotherapy, 15, 143-150. https://doi.org/10.1517/14656566.2014.860964
|
[44]
|
Mo, H.N. and Liu, P. (2020) Targeting MET in Cancer Ther-apy. Chronic Diseases and Translational Medicine, 3, 148-153. https://doi.org/10.1016/j.cdtm.2017.06.002
|
[45]
|
Bardelli, A., Ponzetto, C. and Comoglio, P.M. (1994) Identifica-tion of Functional Domains in the Hepatocyte Growth Factor and Its Receptor by Molecular Engineering. Biotechnology, 37, 109-122.
https://doi.org/10.1016/0168-1656(94)90002-7
|
[46]
|
Ma, P.C., Kijima, T., Maulik, G., Fox, E.A., Sattler, M., Grif-fin, J.D., Johnson, B.E. and Salgia, R. (2003) c-MET Mutational Analysis in Small Cell Lung Cancer: Novel Juxtamem-brane Domain Mutations Regulating Cytoskeletal Functions. Cancer Research, 63, 6272-6281.
|
[47]
|
Ho-Yen, C.M., Jones, J.L. and Kermorgant, S. (2019) The Clinical and Functional Significance of c-Met in Breast Cancer: A Review. Breast Cancer Research, 17, Article No. 52. https://doi.org/10.1186/s13058-015-0547-6
|
[48]
|
Sabbah, M., Najem, A., Krayem, M., Awada, A., Journe, F. and Ghanem, G.E. (2021) RTK Inhibitors in Melanoma: From Bench to Bedside. Cancers (Basel), 3, Article No. 1685. https://doi.org/10.3390/cancers13071685
|
[49]
|
Wang, H., Rao, B., Lou, J., Li, J., Liu, Z., Li, A., et al. (2020) The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 8, Article No. 55. https://doi.org/10.3389/fcell.2020.00055
|
[50]
|
Iveson, T., Donehower, R.C., Davidenko, I., Tjulandin, S., Deptala, A., Harrison, M., et al. (2020) Rilotumumab in Combination with Epirubicin, Cisplatin, and Capecitabine as First-Line Treatment for Gastric or Oesophagogastric Junction Adenocarcinoma: An Open-Label, Dose De-Escalation Phase 1b Study and a Double-Blind, Randomised Phase 2 Study. The Lancet Oncology, 15, 1007-1018. https://doi.org/10.1016/S1470-2045(14)70023-3
|
[51]
|
Shao, Z., Pan, H., Tu, S., Zhang, J., Yan, S. and Shao, A. (2021) HGF/c-Met Axis: The Advanced Development in Digestive System Cancer. Frontiers in Cell and Developmental Biology, 8, Article No. 801.
https://doi.org/10.3389/fcell.2020.00801
|
[52]
|
Sakai, D., Chung, H.C., Oh, D.Y., Park, S.H., Kadowaki, S., Kim, Y.H., et al. (2017) A Non-Randomized, Open-Label, Single-Arm, Phase 2 Study of Emibetuzumab in Asian Patients with MET Diagnostic Positive, Advanced Gastric Cancer. Cancer Chemotherapy and Pharmacology, 80, 1197-1207. https://doi.org/10.1007/s00280-017-3445-z
|
[53]
|
Harding, J.J., Zhu, A.X., Bauer, T.M., Choueiri, T.K., Drilon, A., Voss, M.H., et al. (2019) A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical Cancer Research, 25, 5202-5211. https://doi.org/10.1158/1078-0432.CCR-18-4010
|